AI shows perfect performance in invasive lobular carcinoma
An artificial intelligence (AI) decision-support system may help radiologist...Read more on AuntMinnie.comRelated Reading: SBI: Supplemental screening key to finding interval breast cancers AI performs well with portable breast ultrasound images AI proves comparable to rads for assessing BI-RADS 4 breast lesions ABUS, CEUS could help predict breast cancer treatment response Is axillary scanning needed in diagnostic breast ultrasound? (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - May 23, 2023 Category: Radiology Source Type: news

Elevar Therapeutics Submits New Drug Application to FDA for Combination of Rivoceranib and Camrelizumab as First-Line Treatment Option for Unresectable Hepatocellular Carcinoma
Fort Lee, N.J., May 17, 2023 - Elevar Therapeutics, Inc., a wholly owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for patients who have limited or... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - May 17, 2023 Category: Drugs & Pharmacology Source Type: news

Cabozantinib Plus Nivolumab and Ipilimumab Increases PFS in Renal Cell Cancer
THURSDAY, May 11, 2023 -- Cabozantinib plus nivolumab and ipilimumab yields significantly longer progression-free survival than treatment with cabozantinib plus nivolumab alone among patients with previously untreated, advanced renal-cell carcinoma... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 11, 2023 Category: Pharmaceuticals Source Type: news

Mohs Surgery Improves Survival in Early-Stage Merkel Cell Mohs Surgery Improves Survival in Early-Stage Merkel Cell
Compared with conventional surgery, the use of Mohs significantly improved survival among patients with Merkel cell carcinoma.Medscape Medical News (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - May 9, 2023 Category: Surgery Tags: Dermatology News Source Type: news

SBI: The presence of LCIS indicates increased breast cancer risk
Lobular carcinoma in situ (LCIS) is both a cancer precursor indicator and ...Read more on AuntMinnie.comRelated Reading: Is screening breast MRI needed for women with high-risk lesions? How should architectural distortions on DBT be managed? FES-PET/CT can help detect breast cancer Chest wall ultrasound good alternative after mastectomy AI, breast density assessment spot more interval cancers (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - May 9, 2023 Category: Radiology Source Type: news

SBI: DCIS progression appears as new masses on surveillance imaging
Surveillance imaging of women with ductal carcinoma in situ (DCIS) that ha...Read more on AuntMinnie.comRelated Reading: Half of DCIS-treated women don't get ongoing imaging surveillance Is palpable DCIS more aggressive than screen-detected? Ultrafast MRI shows promise in predicting DCIS upstaging Ultrasound guidance effective in DCIS surgery DWI-MRI predicts whether women's DCIS will upstage after surgery (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - May 8, 2023 Category: Radiology Source Type: news

TriHealth breast cancer patient, surgical oncologist share screening insights
When Ohio House Bill 371 passed last year, insurance companies had to start paying for additional screenings beyond the traditional mammogram for patients with a higher risk of breast cancer. TriHealth patient Jenny Dermody called the additional imaging coverage “a huge blessing” in this episode of the Getting Health Care Right podcast. She took advantage and got a 3D mammogram after her regular one last fall — and the team found lobular carcinoma. Dermody shares her story in this episode… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - May 5, 2023 Category: American Health Authors: TriHealth Source Type: news

Cochrane Lifetime and Emeritus Members
Cochrane is proud to announce new lifetime and emeritus memberships,recognizing the extraordinary contributions of individuals who have made an exceptional, long-standing contribution to Cochrane ’s work and leadership.Cochrane ' s strength is in its collaborative, global community. Over the last 30 years, our members and supporters from more than 130 countries have worked together to produce credible, accessible health information and help inform health decision-making. Though we are spread out across the globe, our shared passion for health evidence unites us.Cochrane ’s Membership schemehelps reward everyone who hel...
Source: Cochrane News and Events - May 3, 2023 Category: Information Technology Authors: Muriah Umoquit Source Type: news

S2 Episode 2: How Single-Cell Sequencing Can Help in Renal Cell Carcinoma S2 Episode 2: How Single-Cell Sequencing Can Help in Renal Cell Carcinoma
Drs Sumanta Pal and David A. Braun discuss the role of single-cell sequencing as a biomarker in renal cell carcinoma, how it is evolving, and how it might apply in other domains.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 3, 2023 Category: Consumer Health News Tags: Hematology-Oncology InDiscussion Source Type: news

S2 Episode 1: Tissue Biomarkers and Renal Cell Carcinoma S2 Episode 1: Tissue Biomarkers and Renal Cell Carcinoma
Drs Sumanta Pal and Scott Haake discuss the biology of kidney cancer and how to incorporate tissue biomarkers into prospective studies on renal cell carcinoma.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 3, 2023 Category: Consumer Health News Tags: Hematology-Oncology InDiscussion Source Type: news

Molecular Differences Between MCPyV-Negative MCCs and NECs Molecular Differences Between MCPyV-Negative MCCs and NECs
Differentiating Merkel cell polyomavirus-negative Merkel cell carcinomas from neuroendocrine carcinomas is challenging. Can NGS-based mutational analyses help when immunohistochemical studies fail?American Journal of Clinical Pathology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 3, 2023 Category: Consumer Health News Tags: Pathology & Lab Medicine Journal Article Source Type: news

Mayo Clinic Minute: Melanoma Monday -- treating skin cancer with Mohs surgery
Nearly 5 million people in the U.S. will be diagnosed with a form of skin cancer this year, according to the American Cancer Society. May is Skin Cancer Awareness Month and the first Monday in May is Melanoma Monday, a day dedicated to raising awareness for Melanoma prevention and treatment. Dr. Naiara Sbroggio Barbosa, a Mayo Clinic dermatologist, explains how Mohs surgery can be used to treat basal cell carcinoma, squamous cell carcinoma and some… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - May 1, 2023 Category: Databases & Libraries Source Type: news

Janssen Reports First Results from Phase 2 SunRISe-1 Study of TAR-200 and Anti- PD-1 Antibody Cetrelimab in Patients with Bacillus Calmette-Gu érin-Unresponsive Non-Muscle-Invasive Bladder Cancer
CHICAGO, April 30, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the first results from the open-label Phase 2 SunRISe-1 study evaluating the efficacy and safety of TAR-200 monotherapy (a novel investigational intravesical drug delivery system) and cetrelimab monotherapy (an investigational anti-PD-1 monoclonal antibody administered intravenously) in patients with Bacillus Calmette-Guérin (BCG)-unresponsive high-risk non-muscle-invasive bladder cancer (HR-NMIBC), who are ineligible for, or decline, radical cystectomy. The study demonstrated that 72.7 percent of patients treated wit...
Source: Johnson and Johnson - April 30, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news

[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong sales growth in base business of both divisions in the first quarter; Group sales decline due to expected drop in demand for COVID-19 tests
As expected, significantly lower demand for COVID-19 tests leads to a decrease inGroup sales (-3%1 at constant exchange rates [CER] and -7% in Swiss francs); excluding this effect, Group sales grow 8%Pharmaceuticals Divisionsales up 9%; strong demand for newer medicines; Vabysmo for severe eye diseases is already the strongest growth driverDiagnostics Division base business grows 4%, whiledivisional salesare 28% lower due to exceptionally high demand for COVID-19 tests in the first quarter of 2022Highlights in the first quarter:US approval of  Polivy (first-line treatment for an aggressive form of blood cancer)EU approva...
Source: Roche Investor Update - April 26, 2023 Category: Pharmaceuticals Source Type: news

[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong sales growth in base business of both divisions in the first quarter; Group sales decline due to expected drop in demand for COVID-19 tests
Basel, 26 April 2023As expected, significantly lower demand for COVID-19 tests leads to a decrease inGroup sales (-3%1 at constant exchange rates [CER] and -7% in Swiss francs); excluding this effect, Group sales grow 8%Pharmaceuticals Divisionsales up 9%; strong demand for newer medicines; Vabysmo for severe eye diseases is already the strongest growth driverDiagnostics Division base business grows 4%, whiledivisional salesare 28% lower due to exceptionally high demand for COVID-19 tests in the first quarter of 2022Highlights in the first quarter:US approval of  Polivy (first-line treatment for an aggressive form of blo...
Source: Roche Media News - April 26, 2023 Category: Pharmaceuticals Source Type: news